subscribeSubscribe
Sanofi to acquire Provention Bio for $2.9 billion

Sanofi to acquire Provention Bio for $2.9 billion
PRESS RELEASE
14 Mar 2023
Share Share
Provention Bio Announces Closing of Second Tranche with Hercules Capital

Provention Bio Announces Closing of Second Tranche with Hercules Capital
PR NEWSWIRE
02 Feb 2023
Share Share
2022 drug approvals: Biopharma delivered 37 new drugs

2022 drug approvals: Biopharma delivered 37 new drugs
Kevin Dunleavy FIERCE PHARMA
03 Jan 2023
Share Share
Almac Pharma Services Supports Launch of Provention Bio’s TZIELD

Almac Pharma Services Supports Launch of Provention Bio’s TZIELD
CONTRACTPHARMA
13 Dec 2022
Share Share
JDRF and its affiliates celebrate Teplizumab approval

JDRF and its affiliates celebrate Teplizumab approval
GLOBENEWSWIRE
22 Nov 2022
Share Share
Amber Specialty Pharmacy Selected to Dispense TZIELD

Amber Specialty Pharmacy Selected to Dispense TZIELD
BUSINESSWIRE
21 Nov 2022
Share Share
First-of-its-kind Type 1 diabetes drug wins FDA approval

First-of-its-kind Type 1 diabetes drug wins FDA approval
Delilah Alvarado BIOPHARMADIVE
19 Nov 2022
Share Share
U.S. FDA greenlights Provention Bio`s diabetes drug

U.S. FDA greenlights Provention Bio`s diabetes drug
REUTERS
18 Nov 2022
Share Share
Provention`s Biologic Tzield (Teplizumab) Receives Approval in the U.S.

Provention`s Biologic Tzield (Teplizumab) Receives Approval in the U.S.
FDA
17 Nov 2022
Share Share
FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes

FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes
PRNEWSWIRE
17 Nov 2022
Share Share